title: The novel catecholaminergic and serotoninergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes.
abstract: We investigated the effects of the novel catecholaminergic and serotoninergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane ((-)-BPAP) on the synthesis and secretion of neurotrophins, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF), in cultured mouse astrocytes. The protein and mRNA levels of the neurotrophic factors were measured using the enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction methods, respectively. The amounts of NGF, BDNF, and GDNF secreted from astrocytes into the culture medium increased by up to 120, two, and seven times higher than those of the control, respectively, by treatment with 0.35 mM (-)-BPAP for 24 h. The increases in NGF and GDNF induced by the treatment with (-)-BPAP was inhibited by concomitant treatment with actinomycin D for transcriptional blockade. Furthermore, the treatment with (-)-BPAP for 6 h increased the mRNA expression of NGF, BDNF, and GDNF. These results suggest that (-)-BPAP up-regulated neurotrophic factor synthesis in cultured astrocytes.
authors.affiliation: Clinical Research Center, Utano National Hospital, Narutaki, Ukyo, 616-8255, Kyoto, Japan. kiyoeohta@mail.goo.ne.jp
authors.forename: Kiyoe
authors.initials: K
authors.lastname: Ohta
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Ohta
authors.forename: Ikuko
authors.initials: I
authors.lastname: Mizuta
authors.forename: Aya
authors.initials: A
authors.lastname: Fujinami
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Shimazu
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.forename: Fumio
authors.initials: F
authors.lastname: Yoneda
authors.forename: Kyozo
authors.initials: K
authors.lastname: Hayashi
authors.forename: Sadako
authors.initials: S
authors.lastname: Kuno
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism*; D001572:Benzofurans / Q000494:pharmacology*; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism; D002395:Catecholamines / Q000502:physiology; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D051100:Glial Cell Line-Derived Neurotrophic Factor; D051379:Mice; D008813:Mice, Inbred ICR; D020932:Nerve Growth Factor / Q000235:genetics / Q000378:metabolism; D009414:Nerve Growth Factors / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012701:Serotonin / Q000502:physiology; D015854:Up-Regulation
chemical_list: C404200:1-(benzofuran-2-yl)-2-propylaminopentane; D001572:Benzofurans; D019208:Brain-Derived Neurotrophic Factor; D002395:Catecholamines; C495040:Gdnf protein, mouse; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D012701:Serotonin; D020932:Nerve Growth Factor